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Stroke causes irreversible and permanent damage in the brain immediately adjacent to the 
region of reduced blood perfusion. The only Food and Drug Administration (FDA)-
approved drug treatment for acute ischemic stroke is the thrombolytic, tissue-plasminogen 
activator (t-PA), which acts by dissolving the blood clot in the vessel, and restoring proper 
blood flow, but is only effective if administered within 3 hours of onset. However, only a 
few stroke patients are seen within 3 hours of the initial onset of an ischemic stroke and thus 
have the opportunity at full restoration of blood flow with rapid management by t-PA 
therapy. Meanwhile, the irreversible loss of myocytes after myocardial infarction (MI) also 
caused by impaired blood flow, followed by fibrosis of the myocardial scar, infarct 
expansion, concentric hypertrophy, and left ventricular dilation ultimately leads to 
progressive heart failure. Current clinical interventions to minimize the devastating effects 
of myocardial infarction are frequently not sufficient to prevent left ventricular remodeling 
and subsequent development of heart failure, emphasizing the need for more effective 
therapies. 
These two disorders are related by common features as they are both prevalent in the 
elderly worldwide. The obstruction of blood vessels reduces the availability of blood to the 
tissues, causes the specific tissue-related symptoms, and eventually damages or destroys the 
tissues. Despite interventional and medical advances, the number of people suffering from 
these disorders is on the rise. Most importantly, there are currently no effective treatments 
for these ischemic disorders after permanent tissue injury. 
Human umbilical cord blood (HUCB) has been used to treat children with various 
hematological malignant and nonmalignant diseases (Sirchia and Rebulla, 1999). More than 
six thousand HUCB transplantations have been performed worldwide (Laughlin et al., 2001; 
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Tse and Laughlin, 2005; Wagner et al., 1992), since HUCB was first used to successfully treat 
a 5-year-old child suffering from Fanconi anemia in 1988 (Gluckman et al., 1989). Recently, a 
number of reports reveal the many advantages of HUCB cells for cellular therapies, 
especially compared to bone marrow (BM) stem cells. HUCB cells are immature and elicit a 
lower incidence of graft rejection, graft versus host disease (GvHD), and post-transplant 
infections even though they primarily come from an allogeneic origin (Knutsen and Wall, 
1999; Tse and Laughlin, 2005). The immaturity of cord blood stem cells has been implicated 
in the optimal effects of these cells for hematopoietic and somatic organ therapy. Over the 
past years, many researchers have investigated the therapeutic potential of progenitor cells 
found within HUCB for stroke and MI. We have demonstrated that systemic administration 
of HUCB cells provides significant benefits in the stroke and MI animal models. 
Interestingly, rather than the conventional cell replacement mechanism, we advance 
alternative pathways of graft-mediated brain repair involving trophic effects resulting from 
release of various growth factors that afford cell survival, angiogenesis, and anti-
inflammation. Here is a critical literature review of the therapeutic benefits of HUCB stem 
cell transplantation for stroke and MI in pre-clinical experiments. 
2. The nature of human umbilical cord blood cells 
Hematopoietic progenitors in HUCB are the most primitive and are able to repopulate blood 
lineages for a long time (Broxmeyer et al., 1992; Nayar et al., 2002; Todaro et al., 2000). The 
number of myeloid progenitors in HUCB is similar to the number found in BM (Broxmeyer 
et al., 1992), however, HUCB cells have a greater colony-forming ability (Nakahata and 
Ogawa, 1982). Thus, they can be expanded in long-term cultures in vitro using different 
growth factors and have longer telomeres than other adult stem cells (Vaziri et al., 1994). 
Furthermore, it has been shown that HUCB grafts, compared to adult BM stem cells, are 
more efficient at restoring the host’s hematopoietic progenitor cell reservoir (Frassoni et al., 
2003). 
The mononuclear fraction of HUCB, is primarily composed of lymphocytes and monocytes 
(Pranke et al., 2001). It has a comparable B-cell population and a lower absolute number of 
cluster of differentiation 3 positive (CD3+) T-cells but a higher CD4+/CD8+ ratio compared 
to adult peripheral blood (Harris et al., 1992; Pranke et al., 2001). When comparing the 
characteristics of B-cell differentiation in vitro from CD34+ cord blood cells with those of 
peripheral blood, B-cell precursors that are differentiated from cord blood, appear to be 
more immature (Hirose et al., 2001). The relative immunological immaturity of HUCB, 
compared to adult cell sources, is further classified by a higher proportion of immature T-
cells and decreased numbers of mature memory T-cells (Harris et al., 1992). Moreover, cord 
blood lymphocytes express cytokine receptor profiles such as interleukin (IL)-2, IL-6, IL-7, 
tumor necrosis factor (TNF)-┙, and interferon (IFN)-┛ at lower levels compared to adult 
blood cells (Zola et al., 1995) and produce greater amounts of the anti-inflammatory 
cytokines such as IL-10 (Gluckman and Rocha, 2005, Rainsford and Reen, 2002). IL-10 down-
regulates expression of CD86 on dendritic cells (DCs), which may prevent initiation of the T-
cell mediated inflammatory reaction (Buelens et al., 1995). Increased levels of IL-10 may 
stimulate regulatory T-cells, which in turn inhibit antigen-specific immune responses 
(Asseman and Powrie, 1998). HUCB also contains more natural killer (NK) cells but lower 
numbers of CD56+ cytotoxic T-cells (D'Arena et al., 1998). NK cells can inhibit T-cell 
proliferation and reduce TNF- ┙ production (El Marsafy et al., 2001). The DCs, which are the 
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sentinel cells of the body and initiate immune responses within the lymph nodes, in cord 
blood reflect lymphoid DCs that are most likely to be responsible for colonizing neonatal 
tissue, while they are more myeloid in adults (Willing et al., 2007). The lymphoid DCs 
induce T-helper cell 2 (anti-inflammatory) responses, which along with the naïve T-cells, 
may promote down-regulation of immune responses (Arpinati et al., 2000; Willing et al., 
2007). The immaturity of the immunological properties of HUCB cells probably causes a 
prolonged immunodeficient status after HUCB transplantation (Garderet et al., 1998; 
Thomson et al., 2000). This may explain the low incidence of GvHD and viral transmission. 
Such a cellular constitution could also allow for less strict donor-recipient matching 
requirements, hence leading to a shorter waiting period for treatment (Newcomb et al., 
2007). Rocha et al. found that GvHD incidence was significantly lower in children receiving 
HUCB transplants compared to BM recipients when the source was from an human 
leukocyte antigen (HLA)-identical sibling (Rocha et al., 2000).  
The level of maturity of a cell is identified by the cell’s combination of surface antigens. For 
example, the CD34+ population, a marker designated for its role in early hematopoiesis, in 
HUCB can be defined as more primitive than those found in BM because a higher 
proportion of them are negative for CD38, a marker for pre-lymphoid cells (Cardoso et al., 
1993; Conrad and Emerson, 1998). Not only does the mononuclear fraction contain roughly 
1% CD34+ cells but these cells appeared to be more immature than those found in BM 
(Newcomb et al., 2007). Another human antigen, CD133, has also been identified as a 
hematopoietic stem cell marker that may provide an alternative to CD34 for the selection 
and expansion of hematopoietic cells for transplantation (Kobari et al., 2001; Yin et al., 1997). 
It has been shown that about 80% of CD34+ cells express CD133 and more than 97% of CD 
133+ cells are CD133+CD34+ in fresh cord blood (Hao et al., 2003). Although CD133+ cells 
comprised 0.67% of the total mononuclear HUCB cells (Ma et al., 2002), expansion of CD 
133+ and CD133+CD34+ cells was significantly higher than those from the CD34+ cells (Hao 
et al., 2003). These findings suggest that CD133+ cells may be more primitive hematopoietic 
progenitor/stem cells than CD34+ cells. Furthermore, CD133+ cells have been identified in 
fetal brain and in this area they are considered to be neural stem cells (NSCs) (Tamaki et al., 
2002; Uchida et al., 2000). Meanwhile, we identified in vitro two different subpopulations of 
mononuclear HUCB cells- adherent and floating (N. Chen et al., 2005). Whereas the 
adherent cell population mainly contained lymphocytes expressing hematopoietic antigens, 
there are a significant number of stem cell and neural cell antigens expressed on cells in the 
floating population. These results suggest that a nonhematopoietic subpopulation of cells 
exists within the mononuclear fraction of HUCB cells and they seem to have the potential to 
become neural-like cells. Thus, HUCB seems to include a primitive stem cell population that 
may give rise to both hematopoietic and neural cells (Garbuzova-Davis et al., 2006). A recent 
study suggests that the CD133+ population of cells within cord blood can be induced to 
differentiate along specific lineages, but cell-cell contact is required (Park et al., 2009). 
However, as described below, other studies suggest that culture in the presence of specific 
factors is normally sufficient.    
A nonhematopoietic stem cell, the mesenchymal stem cell (MSC), has also been found in 
UCB (Goodwin et al., 2001; Yang et al., 2004). It has been confirmed that MSCs and MSC-like 
progenitors can be isolated from amniotic fluid, placenta, and HUCB. Moreover, MSCs 
derived from HUCB show impressive plasticity and differentiate into cells of all three germ-
line derivatives (Jeong et al., 2004; Lee et al., 2004; Yang et al., 2004). However, determining 
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a definitive phenotype as well as the surface antigens of MSCs from HUCB has proven to be 
controversial, unlike that from BM. HUCB MSCs failed to produce macrophage, 
granulocyte-erythroid-macrophage-megakaryocyte, or granulocyte-macrophage 
hematopoietic colonies in methylcellulose, whereas supernatants from cultured HUCB 
MSCs promoted survival of NT2N neural cells and peripheral blood mononuclear cells 
when cultured under conditions designed to induce cell stress and limit protein synthesis 
(El-Badri et al., 2006). Furthermore, after incubation in neural differentiation medium, 
HUCB MSCs expressed the neural cell surface antigen A2B5, the neurofilament polypeptide 
NF 200, the oligodendrocyte precursor marker 04, intermediate filament proteins 
characteristic of neural differentiation (nestin and vimentin), as well as the astrocyte marker 
glial fibrillary acidic protein (GFAP) and the neural progenitor marker class III -tubulin (El-
Badri et al., 2006). We also demonstrated the immunomodulatory effects of HUCB MSCs 
after co-culture with murine splenocytes (El-Badri et al., 2006). These results indicate that 
HUCB MSCs possess multiple utilities that may contribute to their therapeutic potency in 
the treatment of neurological diseases. 
3. HUCB in preclinical stroke research  
The therapeutic window of current stroke treatment is narrow and restrictive. Many 
patients seen outside of this window suffer from irreversible deficits. This reality should be 
taken into consideration when developing other therapeutic options, especially cell-based 
therapies. HUCB is one of the most promising sources of multipotent stem cells that have 
shown affirmative effects in in vivo studies for the treatment of stroke. We reviewed the 
literature focusing on delivery techniques such as the route of administration, time, and 
dose of HUCB cells given and underlying mechanisms responsible for beneficial effects 
from the transplantation of HUCB cells. 
3.1 Delivery routes, time, and dose of HUCB stem cells 
Chen et al. showed that the intravenous administration of mononuclear HUCB cells at 24 
hours or 7 days after middle cerebral artery occlusion (MCAO) in a rat model of stroke 
significantly improved neurological function (Chen et al., 2001). Upon histological 
examination of the brains, mononuclear HUCB cells were observed mainly in the cortex and 
striatum of the injured hemisphere in the ischemic boundary zone. Few cells were found in 
the contralateral hemisphere. It was determined that some of these mononuclear HUCB cells 
were immunoreactive for the endothelial cell marker blood clotting factor VIII (FVIII), 
GFAP, microtubule-associated protein 2 (MAP2), and neuronal nuclei (NeuN) by 
immunohistochemistry. Xiao et al. produced a line of cells isolated from HUCB that they 
called ‘nonhematopoietic umbilical cord blood stem cells’ by culturing of the mononuclear 
fraction and cell sorting for specific CD antigens (Xiao et al., 2005). A reduction in infarction 
volume was observed after intravenous transplantation of these cells into rats with ischemic 
brain injury. Histological analysis revealed that some of the transplanted cells were double 
labeled for human nuclei and NeuN, even though it was unlikely that they contributed to 
the recovery.  
Meanwhile, we compared the effect of intravenous versus intrastriatal injection of 
mononuclear HUCB cells to assess which route produced the greatest behavioral recovery in 
rats with a permanent MCAO (Willing et al., 2003a). Behavioral improvement was similar 
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for both cell delivery routes. Spontaneous activity was significantly less when cells were 
transplanted 24 hours after stroke compared with non-treated animals. However, 2 months 
after transplantation, significant improvements were found in the step test only after 
intravenous delivery of the mononuclear HUCB cells. Also, in the passive avoidance test, 
transplanted animals learned the task faster than non-transplanted rats. These results 
suggest that intravenous delivery of mononuclear HUCB cells may be more effective than 
direct striatal delivery in producing long-term functional benefits to the stroke animal. Next, 
we investigated the dose effect of mononuclear HUCB cells after MCAO (Vendrame et al., 
2004). Twenty-four hours after MCAO, rats were intravenously infused with from 104 up to 
3-5 x 107 mononuclear HUCB cells. At 4 weeks after infusion, there was a significant 
recovery in behavioral function, when 106 or more mononuclear HUCB cells were delivered. 
Infarct volume analysis showed an inverse relationship between cell dose and damage 
volume, which reached significance at the higher doses of mononuclear HUCB cells. 
Moreover, transplanted cells were observed by immunofluorescence for human nuclei 
antigen expression, to be localized only in the injured brain hemisphere and spleen. Taken 
together, this suggests that there may be a dose relationship between introduced 
transplanted cells, behavioral improvement, and neuronal sparing using mononuclear 
HUCB cell infusion in the MCAO rat stroke model.  
For translation from research to clinical application, it will be important to determine how 
soon after onset, HUCB cells should be transplanted for the best treatment of stroke. Our 
group determined the optimal time to administer these cells after a stroke. Using ischemic 
tissue extracts in an in vitro assay, we investigated the migration capability of mononuclear 
HUCB cells (Newman et al., 2005). This assay revealed increased migration of mononuclear 
HUCB cells towards both the hippocampal and striatal extracts that were harvested 24-72 
hours after stroke. Cytokine-induced neutrophil chemoattractant-1 (CINC-1) and monocyte 
chemotactic protein-1 (MCP-1) were increased in the extracts at 48 hours after MCAO. This 
suggests that these substances probably participate in the cell migration. Further analysis 
showed that growth-regulated oncogene/CINC-1 (the rat equivalent of human IL-8) and 
MCP-1 were expressed in a time-dependent pattern similar to that of the migration assays. 
The chemokines which are present in the supernatant may play a major role in the specific 
mechanisms responsible for the in vivo migration of mononuclear HUCB cells after stroke 
induction (Newman et al., 2005). Recently, we demonstrated that, in vivo, the HUCB 
treatment window is not particularly wide. When we intravenously injected the HUCB cells 
at times ranging from 3 hours to 30 days after MCAO, maximal improvements were 
observed with treatment at 48 hours (Newcomb et al., 2006). According to a recent study by 
Riegelsberger et al., neither the infarct volume nor cleaved caspase 3 activity was 
significantly affected by intravenous HUCB cell transplantation 24 hours after stroke onset 
(Riegelsberger et al., 2011). In addition, a recent study of MCAO in spontaneously 
hypertensive rats demonstrated a therapeutic window of upto 72 hours with intravenous 
injection of 1 x 106 HUCB mononuclear cells based on lesion size and behavioral impairment 
(Boltze et al., 2011a). The different rat species may explain the slightly longer therapeutic 
window compared with our studies. These results are promising in that by using 
mononuclear HUCB cell therapy, the current 3 hour time window of t-PA for the treatment 
of stroke may be extended to at least 24 hours after the stroke event. These findings suggest 
that relatively delayed systemic transplantation of HUCB cells failed to produce 
neuroprotective effects in a permanent stroke rat model. Taken together these results 
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suggest that the grafts actually exist over a very short time frame to either appropriately 
control the immune system or provide secretory products to cells within the brain to confer 
therapeutic effects.  
3.2 Probable mechanisms responsible for neural protection 
Although several reports revealed that HUCB cells expressed neural phenotypes both in 
vitro and in vivo (Garbuzova-Davis et al., 2003; Ha et al., 2001; Sanchez-Ramos et al., 2001; 
Zigova et al., 2002), few cord blood cells survive in the ischemic region compared to the 
number of infused cells (Chen et al., 2006; Vendrame et al., 2004, 2005; Willing et al., 2003a, 
2003b). In addition, two studies using mannitol to permeate the blood brain barrier showed 
that the passage of growth factors into the brain following MCAO and neonatal hypoxic 
ischemia was more important than cell migration from the circulation following intravenous 
injection (Borlongan et al., 2004; Yasuhara et al., 2010). These findings suggest that cell 
replacement is not the primary mechanism responsible for the functional improvements 
seen in these animal studies. Recent research in our team has found that HUCB may not 
only act as a cell replacement source, but also as a neurotrophic, neuroprotective and anti-
inflammatory agent. We found that there was an increase in the number of CD45+/CD11b+ 
and CD45+/B220+ B-cells in the brain of rats with permanent MCAO, while the number of 
CD45+/CD11b+ and CD45+/B220+ B-cells in the brain significantly decreased after 
mononuclear HUCB cell transplantation (Vendrame et al., 2005). The reduction of 
CD45+/CD11b+ cells is of particular interest, given that chronic microgliosis is believed to 
mediate neuronal damage, not only in ischemic injury but also in other neurodegenerative 
diseases (Streit et al., 1999; Tan et al., 1999). HUCB treatment also decreases the 
proinflammatory cytokines such as TNF-┙ and IL-1┚, in the brain following stroke as well as 
reducing the presence of both activated microglia and astrocytes (Vendrame et al., 2005). 
Therefore, the potential anti-inflammatory effects of HUCB therapy may protect against 
neuronal death while evidence suggests that the CD34+ component of the transplant may 
facilitate revascularization (Taguchi et al., 2004). These cellular changes were accompanied 
by decreases in mRNA and protein expression of pro-inflammatory cytokines in the brain of 
stroke animals treated with mononuclear HUCB cells. In our next studies, we revealed that, 
following MCAO, rat spleen size was decreased concomitantly with their CD8+ T-cell counts 
(Vendrame et al., 2006). Interestingly, the MCAO-induced reduction in spleen size 
correlated with the extent of ischemic damage, however, HUCB cell treatment prevented the 
reduction in spleen weight and splenic CD8+ T-cell counts, as well as reducing the degree of 
brain injury. Additionally, splenocyte proliferation assays demonstrated that HUCB cell 
treatment opposed MCAO associated T-cell proliferation by increasing the production of IL-
10 while decreasing IFN-┛.  
As mentioned above, the HUCB cell preparation is a mixed population composed of 
immature T-cells, B-cells, monocytes/macrophages, and stem cells. Thus, it is important to 
determine whether the beneficial effects of HUCB injection can be attributed to a specific cell 
population. Recently, we found that the whole mononuclear fraction of cord blood, stem 
cell-, T-cell-, and B-cell-depleted preparations improved the function of the impaired left 
forelimb to a similar extent that exceeded the performance of MCAO-only animals (Womble 
et al., 2009). However, animals that received the monocyte/macrophage-depleted HUCB 
preparation performed more poorly than those receiving the other HUCB cells. 
Additionally, HUCB administration significantly reduced MCAO-induced hyperactivity, 
www.intechopen.com
 
Human Umbilical Cord Blood Stem Cells Rescue Ischemic Tissues 
 
41 
while depletion of stem cells, monocytes (CD14+), and B cells prevented this recovery 
following stroke. These results suggest that stem cells, monocytes (CD14+), and B cells are 
critical to HUCB-induced recovery following stroke. A study performed in Germany 
confirmed that the mixed mononuclear cell population was most effective at 
neuroprotection against ischemia caused by MCAO in a spontaneously hypertensive rats 
(Boltze et al., 2011b). They showed that CD34+ cells contributed to this effect in vitro against 
oxygen-glucose deprivation (OGD), but did not appear to be important in vivo, since a 
CD34- cell population from HUCB was equally effective.  
The expression of cytokines and chemokines produced by HUCB cells under various culturing 
conditions was also investigated (Newman et al., 2006). The heterogeneous cells from 
mononuclear fractions of HUCB produced a variety of cytokines when grown in various 
culture conditions. In particular, IL-8, MCP-1, and IL-1┚ that have been implicated as the first 
line of defense in the inflammatory reaction, are more extensively produced than other 
chemokines in the human body, especially the brain. These results suggest that these factors 
may be partially responsible for the functional improvements that were observed in the animal 
stroke models investigating the therapeutic use of HUCB cells. On the other hand, we recently 
showed that chemokines are also elevated in the ischemic brain area in an in vivo study (Jiang 
et al., 2008). MCP-1 and macrophage inflammatory protein (MIP)-1┙ seem to play a role in the 
infiltration of monocytes into the central nervous system under pathological conditions 
(Babcock et al., 2003; Glabinski et al., 1998). We found that MCP-1 and MIP-1┙ expression were 
significantly increased in the ischemic brain, and significantly promoted HUCB cell migration 
compared to the contralateral side (Jiang et al., 2008). This cell migration was neutralized with 
polyclonal antibodies against MCP-1 and MIP-1┙. Chemokine receptors were also expressed 
on the surface of transplanted HUCB cells. These findings suggest that the increased 
chemokines within the ischemic lesion can bind surface receptors on the HUCB cells, and 
induce homing of systemically delivered HUCB cells into the CNS in vivo. Recently, Ou et al. 
showed the potential of intravenous transplantation of HUCB CD34+ cells transfected with the 
glial cell line-derived neurotrophic factor (GDNF) gene to exert therapeutic benefits in 
spontaneous hypertensive rats exposed to a transient MCAO (Ou et al., 2010). The stroke 
animals transplanted with GDNF-modified CD34+ cells showed a significant increase in 
GDNF protein levels in the infarcted hemisphere, reduced brain infarction volume, and 
enhanced functional recovery compared to those that received CD34+ cells only. 
The immune system and inflammation are known to play a role in the development of 
stroke. Possible mechanisms of action for HUCB cells include the modification of this effect. 
Using an organotypic slice culture and OGD, a recent study showed that an intact immune 
system is not required for the beneficial effects of HUCB cells (Hall et al., 2009a). Cell 
survival was increased and the release of nitric oxide by resident microglia (an innate 
inflammatory response) was reduced back to normal levels following incubation with the 
cells. Further study showed that the secretion of IL-1 by microglia was impaired following 
hypoxia in the presence of HUCB cells and microglia viability was also decreased (Jiang et 
al., 2010). In vivo, HUCB cells were shown to impair the recruitment of pro-inflammatory 
microglia and hence the secretion of matrix metalloproteinase 9 and nitric oxide at the site of 
injury following MCAO (Leonardo et al., 2010). The microglia found at the site of injury 
tended to be of a ramified shape, which is believed to be a quiescent inactive form.  
Protein and microarray analysis of neuronal co-cultures with HUCB cells following OGD 
revealed the upregulation of a number of specific genes which coincided with improved 
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survival (Shahaduzzaman et al., 2010). Several of these genes e.g. peroxiredoxin were 
verified as being upregulated in vivo also, demonstrating that transplantation of HUCB cells 
promotes survival gene expression within the brain. OGD treatment of PC12 cells followed 
by co-culture with HUCB also demonstrated increased cell survival which was shown to be 
related to the appearance of antioxidants as well as neurotrophic and angiogenic factors 
(Arien-Zakay et al, 2009).  
The majority of studies on stroke and potential therapies focus on the neurons. However, 
ischemia also affects the white matter and therefore therapies should focus on both the 
neurons and the oligodendrocytes that myelinate the axons found in the white matter. Two 
recent studies by the Willing and Pennypacker group demonstrate that infusion of HUCB 
cells 48 hours after MCAO was also able to protect oligodendrocytes by reducing caspase 3 
activation (Hall et al., 2009b) and promoting the expression of genes associated with 
oligodendrocyte survival, proliferation and function (Rowe et al., 2010). A further study 
using HUCB-derived MSCs transduced to express hepatocyte growth factor revealed 
increased behavioral recovery and enhanced remyelination in an intracranial hemorrhage 
model compared to untransduced MSCs (Liu et al., 2010). In the latter study, the cells were 
transplanted one week after hemorrhage directly into the left ventricle. These studies 
demonstrate an additional means by which HUCBs could promote recovery from a stroke 
by aiding survival of oligodendrocyte survival and myelination of axons.  
While the majority of studies suggest mechanisms other than cell replacement, a recent 
study in canines demonstrated survival of intra-arterially injected HUCB-derived MSCs in a 
thromboembolic brain ischemia model at 4 weeks (Chung et al., 2009). The cells were 
injected one day after lesion and were shown to decrease the lesion volume and differentiate 
into neurons and astrocytes in the neighborhood of von Willebrand factor-positive 
endothelial cells suggesting an association with new blood vessels. 
4. HUCB in preclinical myocardial infarction research  
As shown in stroke investigations, the mechanisms by which HUCB stem cells protect 
cardiomyocytes and improve cardiac function seem to be complex and multifactorial. 
Transplanted HUCB cells can differentiate into cardiomyocyte-like cells (Cheng et al., 2003; 
Wu et al., 2006), induce neovascularization in the necrotic area (Botta et al., 2004; Ma et al., 
2005; Wu et al., 2007a), modulate the inflammatory reaction induced by ischemic cascades 
(Henning et al., 2006), and secrete growth factors including vascular endothelial growth 
factor (VEGF) (Hu et al., 2006; Tang et al., 2005). However, there are some in vitro studies 
that suggest that HUCB stem cells in culture do not differentiate into cardiomyocytes. Roura 
et al. used a number of different methods including culture of HUCB cells with 5-
azacytidine, early cardiomyogenesis growth factor cocktails, Wnt signaling activators or 
direct neonatal rat cardiomyocyte contact and did not observe any transdifferentiation 
(Roura et al., 2010). By comparison, Avitabile et al. recently reported that CD34+ HUCB cells 
adopted a cardiomyocyte-like phenotype following co-culture with mouse neonatal 
cardiomyocytes not due to transdifferentiation, but instead by cell fusion with the neonatal 
cardiomyocytes (Avitabile et al, 2011). These studies would seem to suggest that the in vivo 
influences which appear to cause transdifferentiation (Cheng et al., 2003; Wu et al., 2006), 
may not be adequately modeled in vitro. 
The optimal timing and dose of HUCB stem cell administration for treating MI are also 
critical issues as shown in the animal stroke studies. In most of the previous investigations, 
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HUCB stem cells that were administered within 24 hours after MI exerted benefits on 
cardiac function (Botta et al., 2004; H. K. Chen et al., 2005; Henning et al., 2004; Hirata et al., 
2005). By contrast, a wide range of HUCB cell numbers were examined in the MI animal 
models and functional benefits seem to be partly dose-dependent (Botta et al., 2004; H. K. 
Chen et al., 2005; Henning et al., 2004; Hirata et al., 2005; Kim et al., 2005; Ma et al., 2005). 
Meanwhile, as with stroke treatments, a variety of administration routes for HUCB cells, 
including intramyocardial injection, intracoronary injection and intravenous routes, were 
demonstrated as effective and safe. Henning et al. looked at a variety of doses and a variety 
of routes within 2 hours of ligation of the left coronary artery (Henning et al., 2007). They 
found that intramyocardial, intra-arterial and intravenous injection of cells, all produced 
similar significant reductions in infarct size when examined 1 month later, but with different 
optimum doses of cells (4 x 106, 4 x 106 and 16 x 106 respectively) and concluded that 
intramyocardial injection appeared to be best. Below we review further reports focusing on 
the delivery routes of HUCB stem cells to treat MI in animal models. 
4.1 Intramyocardial injection 
Direct transplantation of HUCB stem cells into the myocardium of the infarcted heart has 
been widely investigated in in vivo studies due to the advantage that it provides a direct 
route to the damaged area. Hirata et al. showed the therapeutic effects of HUCB CD34+ cells 
on MI in rats (Hirata et al., 2005). CD34+ cell transplantation significantly improved 
ventricular function as revealed by echocardiography and hemodynamic analysis. 
Immunohistochemistry studies for human CD34, CD45, and CD31 (Platelet endothelial cell 
adhesion molecule; PECAM-1) revealed that transplanted HUCB cells survived in the host 
rat myocardium. These findings suggest that transplanted HUCB cells survived, enhanced 
neovascularization and improved cardiac function after MI in the animal models. 
Interestingly, Higuchi et al. recently showed, using iron oxide and sodium iodide symporter 
reporter gene transfected CD34+ HUCB cells, that transplanted cells did not survive for 
more than 7 days when 4 x 106 cells were injected directly into normal rat hearts (Higuchi et 
al, 2009).  This suggests that the damaging effects of a myocardial infarction may promote 
the survival of transplanted cells. Botta et al. transplanted different subpopulations of HUCB 
cells into the peri-ischemic area at 24 hours after left anterior descending coronary artery 
(LAD) ligation in the non-obese diabetic–severe combined immune deficient (NOD-SCID) 
mouse model (Botta et al., 2004). They showed that CD34+KDR+ (kinase insert domain 
receptor) cells or CD34+ cells significantly improved the rate of rise of left ventricular 
pressure (dP/dt) and left ventricle (LV) end diastolic pressure in cardiac function after MI, 
whereas the same number of CD34+KDR- cells did not have any benefit. In histological 
studies, a limited number of human nuclear antigen positive cells were observed within the 
cardiomyocytes of mice receiving CD34+KDR+ HUCB cells. These results suggest that 
CD34+KDR+ cells are probably an active subpopulation within CD34+ cells. Their 
remarkable resistance to apoptosis and angiogenic ability may contribute to their beneficial 
effects on the damaged cardiac tissues.  
Meanwhile, Henning et al. injected 1 x 106 HUCB mononuclear cells into the infarcted 
myocardium 1 hour after rats underwent LAD ligation (Henning et al., 2004). Compared to 
the vehicle group, the ejection fraction of the HUCB cell-treated group was not decreased 
significantly at 1 month, but progressively increased at 3 and 4 months. At 4 months, in the 
HUCB cell-treated group, anteroseptal wall thickening and increased dp/dt (max) were 
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markedly greater than in the vehicle group. Infarct sizes in the HUCB cell treated group 
were smaller than the vehicle group at 3 and 4 months. These findings suggest that HUCB 
cell transplantation substantially reduces infarct size associated with improvement of left 
ventricular function in the rat MI model. Of interest, Kim et al. reported that HUCB cells 
improved cardiac function even when transplanted 4 weeks after ischemia (Kim et al., 2005). 
In this study, the distal LAD of Yorkshire pigs was occluded by endovascular coil 
embolization. Human unrestricted somatic stem cells (USSCs) isolated from HUCB 
following culturing of the mononuclear fraction under specific conditions (Kogler et al., 
2004) or culture media were directly injected into the infarcted area at 4 weeks after 
ischemia. At 4 weeks after transplantation, single-photon emission computed tomography 
technetium 99m sestamibi radioisotope scans revealed improved regional perfusion and 
wall motion of the infarct region in the cell-treated group compared to the non-treated 
control group. Ejection fraction decreased in the control group while it increased in the 
transplant group. The grafted cells were detected 4 weeks after transplantation by both 
immunohistochemistry and in situ hybridization, and they improved regional and global 
function after MI. Transplanting 1 x 105 or 1 x 106 USSCs intramyocardially, 20 minutes after 
ligation in a rat model, was recently shown to lead to a dose-dependent generation of 
human cardiomyocytes and vasculogenesis which could be detected 4 weeks later. This was 
determined by the colocalization of cardiac troponin-I and human nuclear antigen as well as 
class I HLA staining and smooth muscle actin and von Willebrand factor and human 
nuclear antigen respectively (Iwasaki et al, 2009). These findings suggest that USSCs from 
HUCB also can be a good candidate for cell-based therapies to treat MI and suggest that 
they may function to promote new blood vessel growth and cell replacement. Wu et al. also 
reported a significant improvement of cardiac function in rats with MI that were treated 
with HUCB-derived stem cells compared to the control untreated group (Wu et al., 2007b). 
Four weeks after transplantation, histological studies revealed that some of the grafted 
HUCB-derived stem cells survived in the host infarcted myocardium and accumulated 
around arterioles and scattered in capillary networks. Some of the cells expressed cardiac 
troponin-T, von Willebrand factor, and smooth muscle actin, suggesting that transplanted 
HUCB-derived stem cells in the infarcted myocardium can differentiate into cardiomyocytic, 
endothelial, and smooth muscle cells to repair damaged myocardium. The capillary and 
arteriole density were also significantly elevated in the HUCB cell-treated group, while the 
number of apoptotic cells decreased significantly. Taken together, cardiogenesis and 
angiogenesis probably exert a favorable influence on the recovery of cardiac function even 
after chronic administration of HUCB cells in the animals with acute MI. Hu et al. also 
demonstrated that angiogenesis induced by transplanted cells plays a major role in cardiac 
remodeling and improvement of cardiac function in animal MI models (Hu et al., 2006). 
HUCB mononuclear cells were transplanted into the marginal area of the infarcted 
myocardium immediately after LAD ligation. One month after MI, the grafted cells survived 
in the host heart and the collagen density in the LV was significantly lower in the 
transplanted group, which coincided with higher mRNA expression of VEGF. These results 
suggest that angiogenesis promoted by transplanted HUCB mononuclear cells in the 
infarcted area play a critical role in cardiac repair in the MI animal models. Recently, Hu et 
al. investigated the therapeutic efficacy and feasibility of intramyocardial transplantation of 
1 x 106 human umbilical cord blood-derived endothelial progenitor cells (hUCB-EPCs) in 
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rats with acute MI (Hu et al., 2009, 2010). These cells were obtained by culturing adherent 
cells from the mononuclear fraction under specific media conditions. The cell therapy group 
had increased microvessel formation and a decreased degree of myocardial fibrosis 
compared to the control non-treated group. The increased microvessel formation was shown 
to come from both upregulation of endogenous rat cells (as shown by increased rat 
proliferating cell nuclear antigen and rat PECAM expression) and colocalization of human 
nuclear antigen and CD31 and anti-VIII staining. Moreover, the degree of myocardial 
fibrosis was less than that of the control group. The improved global heart function and 
decreased cardiac fibrosis in rats with acute MI implies the potential benefit of hUCB-EPC 
transplantation. 
Meanwhile, Henning et al. revealed that the transplantation of HUCB cells attenuated the 
inflammatory and immune reaction induced by ischemic cascades (Henning et al., 2006), 
which likely contributed to the cardiac regeneration of the infarcted heart. Implantation of 
HUCB cells into infarcted myocardium of non-immunosuppressed rats within 2 or at 24 
hours after LAD occlusion, limited the expression of pro-inflammatory cytokines such as 
TNF-┙, MCP-1, MIP-1┙, and IFN-┛ in the infarcted myocardium and it may be associated 
with significant decreases in infarct volume. Further analysis was carried out by 
transplanting 4 x 106 cells and performing cytokine analysis and inflammatory cell 
recruitment at 2, 6, 12, 24 and 72 hours after LAD ligation (Henning et al., 2008). They 
observed that the infiltration of inflammatory cells and secretion of inflammatory cytokines 
was significantly reduced by HUCB cells within 2 hours compared to non-treatment after 
LAD occlusion and this was maintained through to 72 hours. 
The number of cells required to be effective in clinical applications, is likely to mean that the 
cells would need to be expanded in vitro prior to delivery. Senegaglia et al. investigated 
whether in vitro expansion of CD133+ endothelial progenitor cells derived from HUCB 
affected their ability to improve the left ventricular ejection fraction following MI in a rat 
model (Senegaglia et al., 2010). 200,000 expanded or purified (non-expanded) cells were 
transplanted intramyocardially 7 days after infarction and the left ventricular ejection 
fraction was found to be equally improved. This suggested that in vitro expansion did not 
alter the transplanted cell’s function suggesting that it may be safe to expand these cells in 
vitro. Further studies would be necessary to see if any benefit is conferred by expansion 
(apart from the more readily available supply of cells) since the authors did report that the 
expanded cells expressed VEGF mRNA whereas non-expanded did not in vitro. However 
the expansion methods are currently not sufficiently reliable to be used routinely (see later).  
Of interest, Ma et al. compared the effects of cell transplantation between BM stem cells and 
HUCB stem cells for injured myocardium. HUCB CD133+ cells (5 x 105) were injected 
directly into the infarcted myocardium induced by cryoinjury of NOD/SCID mice (Ma et 
al., 2006a; 2006b).  An equivalent number of CD133+ BM cells were transplanted and a sham 
injection was performed in the respective control groups. Both BM CD133+ and HUCB 
CD133+ cells increased capillary density in the injured myocardium, whereas only BM 
CD133+ cells improved myocardial contractility assessed by echocardiography in vivo. 
Armiñán et al. also suggest that mesenchymal stem cells derived from bone marrow maybe 
more effective than CD34+ cells isolated from UCB following intramyocardial injection into 
a nude rat model of MI 7 days after infarction (Armiñán et al., 2010). Both cell types led to 
improved cardiac function, cardiac cell proliferation and neoangiogenesis, but the MSCs 
appeared to be more effective at reducing infarct size. However, it is important to note that 
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in their study Armiñán et al. used twice as many MSCs than CD34+ cells (1.2 x 106 vs. 6 x 105) 
making it difficult to really make a comparison. Gaebel et al. demonstrated that MSCs 
derived from 3 different sources – human BM, HUCB and human adipose tissue – were 
differentially able to heal male SCID mice after LAD ligation (Gaebel et al, 2011). 400,000 
cells were transplanted immediately after ligation and the hearts examined 6 weeks later. 
While each cell type had some benefit, the best results were seen with the BM-derived cells. 
However, they also showed that HUCB-derived MSCs had a lower proportion of CD105+ 
(endoglin, a type 1 membrane glycoprotein) cells compared to the other sources, which 
decreased further with additional passaging. A purified preparation of CD105+ HUCB cells 
was shown to possess a similar benefit as BM-derived MSCs. Endoglin is known to be 
involved in the development of the cardiovascular system and vascular remodeling, which 
may explain its apparent importance in transplanted cells (Gaebel et al, 2011). 
Using a right ventricle overload model, autologous sheep UCB mononuclear cells were shown 
to improve the diastolic properties of the right ventricle (Yerebakan et al., 2009). The authors 
suggested that this occurred due to increased angiogenesis. This is one of the few examples of 
autologous UCB cell transplantation for myocardial impairments so far reported.  
4.2 Systemic injection 
A number of studies explored the usefulness and effectiveness of the systemic route 
including intravenous and intra-arterial administration, which could have clinical potential 
because the procedure is minimally invasive and a minimal burden to the recipients 
suffering from critical diseases, even though it raises the doubt of adequate homing to the 
lesion. However, as shown in animal stroke or MI models, there has been emerging 
evidence suggesting that a significant proportion of the HUCB cells which are systemically 
administered, will migrate into the infarcted brain or heart lesion and the animals show 
improvement in their behavioral deficits.  
Ma et al. revealed the homing ability of HUCB mononuclear cells that were injected in the 
tail vein of NOD/SCID mice that had (MI+) or had not (MI–) received ligation of the LAD 
(Ma et al., 2005). Human DNA (hDNA) was detected in marrow, spleen, and liver of both 
MI+ and MI– mice from 24 hours to 3 weeks after cell injection. By contrast, hDNA was 
found in the hearts of 53% of MI+ mice but in none of the MI– mice. Infarct size was smaller 
and collagen deposition was reduced in the cell-treated group. Capillary density in the 
border zone of the MI was approximately 20% higher, and clusters of HUCB-derived cells 
were detected in the perivascular interstitium in cell-treated MI+ mice, though the vast 
majority of new vessels seemed to originate from the endogenous mouse cells. There was no 
evidence of cardiomyocyte differentiation of the intravenously grafted HUCB mononuclear 
cells. Interestingly, in infarcted myocardium, stromal cell-derived factor (SDF)-1 mRNA was 
expressed approximately 7-fold higher than in normal hearts. These results suggest that 
systemically administered HUCB cells can migrate into the faraway infarcted lesion where 
they play a role in neovascularization, and beneficially influence tissue-remodeling 
processes. Leor et al. administered HUCB-derived CD133+ progenitor cells intravenously at 
7 days after permanent coronary artery ligation in athymic nude rats (Leor et al., 2006). One 
month after transplantation, LV fractional shortening was much improved. Moreover, 
anterior wall thickness decreased significantly in control group but not in HUCB cell-treated 
group. The grafted HUCB cells were found to have migrated and survived in the infarcted 
myocardium on microscopic examination. Human originated-cells were detected near vessel 
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walls and LV cavity in the HUCB cell-treated rats. They were incorporated into endothelial 
cells in six out of the nine cell-treated animals. Scar tissue from cell-treated animals was 
significantly populated with autologous myofibroblasts as indicated by colocalization of 
HLA-DR and alpha-smooth muscle actin staining. These findings suggest that intravenous 
transplanted HUCB cells can migrate, survive, and be incorporated into the host 
myocardium and produce functional recovery in animal MI models.  
A couple of studies focused on the mechanisms of how the systemically transplanted HUCB 
cells are recruited into the site of tissue damage. Henning et al. revealed that the greatest 
HUCB cell migration into the infarcted myocardium persisted at 2 and 24 hours after LAD 
occlusion (Henning et al., 2006). Increased SDF-1 in the infarcted myocardium attracts 
circulating stem cells through the CXCR4 receptor, leading to activation of surface integrins 
and subsequent recruitment into the vasculature (Ma et al., 2005). These findings suggest 
that the recruitment of transplanted cells to the injured site was likely due to the 
concentrations of chemoattractants within the ischemic and infarcted tissues. 
Another study using an unspecified number of cells attempted to explore the optimal time 
for transplantation via the caudal vein (Xing et al., 2009). They injected HUCB cells 1, 5, 10 
or 30 days after LAD ligation and they measured cardiac function 4 weeks later. Animals 
transplanted 5 and 10 days after LAD ligation showed improved cardiac function, with the 
best results occurring in the 10 day transplant animals. The best survival, more pronounced 
angiogenesis and VEGF expression was observed within these animals, though no evidence 
of cardiac regeneration was seen. The authors proposed that the angiogenic effects were the 
main cause of the improvement. It is worth noting that the authors characterized the cells 
prior to transplantation and showed that only 35-42% of the cells were CD34+.  
Lineage-depleted HUCB cells that express high levels of the cytosolic enzyme aldehyde 
dehydrogenase (ALDH) were found to possess a high long term repopulation potential 
whereas cells with low levels of ALDH had negligible long term repopulation potential 
(Sondergaard et al., 2010). Intravenous administration of these cells one day after LAD 
ligation in NOD/SCID mice showed specific localization to the injured area within 48 hours 
and engraftment was higher 4 weeks later using the high ALDH expressing population 
compared to the low expressing population (Sondergaard et al., 2010). However none of the 
transplanted cells were observed to became cardiomyocytes, but a few became endothelial 
cells and the surviving cells were associated with increased vascular density. It is worth 
noting that only a small number of cells were transplanted (~400,000 cells), which may not 
be sufficient to see the best effects when administered systemically. These studies show that 
there are a number of cell types in HUCB which differ in their CD markers and enzyme 
levels which could affect their ability to be effective.  
4.3 Intracoronary delivery 
Intracoronary injection can be classified as via the systemic route as it is a subtype of intra-
arterial infusion. This method is somewhat more complicated than peripheral access, but 
can easily be accomplished within several minutes in a well-equipped coronary suite with 
well-trained physicians. Thus, this method is directly applicable to the real clinical situation. 
Moreover, intracoronary delivery has an advantage over the intravenous route since the 
stem cells can be delivered directly to the infarcted myocardium without passing through 
the systemic circulation. This aspect alleviates the possibility of systemic cell loss such as cell 
trapping within the lungs and spleen. However, there is also a disadvantage with intra-
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arterial infusion, since the transplanted cells can form clumps or aggregates if very large 
quantities of cells are infused, which can subsequently become an embolus (Qian et al., 
2006).  
While a number of studies have examined the feasibility and efficacy of intracoronary 
infusion of BM stem cells or peripheral blood-derived mononuclear cells for treating MI in 
animal and human models (Bartunek et al., 2005; Manginas et al., 2007; Qian et al., 2006), 
there are few published studies using HUCB cells. Moelker et al. failed to show 
improvement of LV function by intracoronary administration of HUCB cells after MI 
(Moelker et al., 2007). In this study, approximately 108 HUCB stem cells were injected via the 
intracoronary route 1 week after MI and reperfusion in a swine model. By this time point, 
end-diastolic volume and LV mass were larger, while ejection fraction was smaller. Regional 
wall thickening in the left circumflex coronary artery area became akinetic. There was no 
difference in global and regional LV function at 5 weeks between MI animals receiving 
HUCB stem cells or normal medium, while surprisingly the infarct size after HUCB stem 
cell treatment was significantly larger. Transplanted HUCB cells survived only in the infarct 
border zone at 5 weeks and did not express cardiomyocyte or endothelial markers. Of 
interest, histological examination revealed that HUCB stem cells transplanted through 
intracoronary infusion caused micro-infarctions by obstructing vessels. Although the 
feasibility and efficacy of intracoronary delivery of HUCB could not be determined because 
there has been few studies about this issue, these results raise safety concerns due to embolic 
infarction related with the high dose of transplanted HUCB cells required for the 
intracoronary route (Moelker et al., 2007; Qian et al., 2006). 
4.4 Tissue engineering and gene modification 
Recent investigations focusing on gene therapy or tissue engineering demonstrate that the 
combination of stem cell and gene modification may be a useful treatment modality for MI 
treatment (Mangi et al., 2003; Matsumoto et al., 2005). However, gene manipulation of stem 
cells outside the body and in the laboratory before transplantation raises safety problems as 
well as possible moral and ethical concerns when it is applied clinically. 
Cortes-Morichetti et al. examined the feasibility of a collagen matrix seeded with HUCB 
stem cells and their engraftment onto infarcted ventricles (Cortes-Morichetti et al., 2007). 
Echocardiography and histological examination implied that the cell-loaded matrix and the 
cell implants appeared to be an effective alternative to prevent post-MI ventricular dilation 
and cardiac remodeling compared to either HUCB cells or collagen matrix alone-treated 
groups. These results suggest that stem cell implantation accompanied with tissue 
engineering techniques, probably augment the efficacy of simple cellular therapy and could 
emerge as a new therapeutic modality to prevent adverse remodeling and progressive heart 
failure. 
Meanwhile, Chen et al. studied the efficacy of HUCB cells with genes inserted to overexpress 
angiogenic factors that were subsequently transplanted into infarcted ventricles (H. K. Chen 
et al., 2005). In this study, HUCB CD34+ cells were transfected with adeno-associated virus 
(AAV) vectors encoding either human angiopoietin (Ang1; AAV-Ang1) or VEGF (AAV-
VEGF) cDNA alone, or both combined (AAV-Ang1 plus VEGF). After LAD ligation in SCID 
mice, they administered the expanded CD34+ cells transduced with AAV-Ang1, AAV-VEGF 
or AAV-Ang1 plus VEGF intramyocardially at the left anterior wall. Western blot analysis 
revealed that Ang1 and VEGF expressions were increased in the CD34+ cells transduced 
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with AAV-Ang1 and AAV-VEGF, respectively. Infarct size significantly decreased and 
capillary density remarkably increased after treatment with CD34+/AAV-Ang1 plus VEGF 
compared to the treatment with CD34+ cells only. Combination therapy with CD34+/AAV-
Ang1, CD34+/AAV-VEGF, and CD34+/AAV-Ang1 plus VEGF, all expressed remarkably 
higher cardiac performance in echocardiography than the CD34+ cells alone 4 weeks after 
MI. These results suggest that combination therapy with HUCB CD34+ cells and 
overexpression of both Ang1 and VEGF genes decreases infarct size, improves cardiac 
dysfunction and elevates capillary density in acute MI in mice to a greater extent compared 
to HUCB hematopoietic stem cell only transplantation. 
Pretreatment of HUCB cells with oxytocin prior to transplant has been shown to promote 
their activity. Oxytocin stimulates cell proliferation and may promote cardiomyogenesis 
(Kim et al., 2010). Kim et al. transplanted 106 pretreated cells intramyocardially after LAD 
ligation and found that cardiac fibrosis and macrophage (CD68+) infiltration was reduced by 
oxytocin pretreatment. Engraftment, connexion 43 expression and cardiac contractility were 
increased, but angiogenesis did not appear to be altered in animals administered pretreated 
cells (Kim et al., 2010). This suggests that oxytocin pretreatment may increase the 
proliferation and differentiation of the transplanted cells, but does not appear to influence 
blood vessel growth.  
5. Conclusions 
Ischemic insults to neural tissue and the myocardium involve complicated inflammatory 
cascades that eventually lead to a pronounced cell death adjacent to the obstructed 
vasculature. The appropriate delivery of HUCB cells most likely prevents the apoptotic 
cascade, regenerates damaged cells and tissues, and modulates the inflammatory response 
to ischemic injury. Another advantage in using HUCB cells for the treatment of ischemic 
damage is the potential restoration of vascularity since cord blood contains endothelial 
progenitor cells and hematopoietic stem cells which may be of use in neovascularization 
therapy.  
However, there are still a number of obstacles that prevent the routine application of HUCB 
cell transplantation to treat human stroke or MI patients as follows. First, safety has not been 
effectively determined in terms of immunological rejection when allogeneic transplantation 
is considered. HUCB cells are likely to be used primarily for transplantation into allogeneic 
recipients, though as HUCB cell banking becomes more popular autologous transplants 
may become more common in the future. Although HUCB cells are less immunogenic, long 
term studies should be considered to evaluate the long term safety with or without 
immunosuppression. Jozwiak et al. and Yang et al. have reported on using HUCB cells for 
the safe treatment of a single case of global brain ischemia and in a number of neurological 
disorders (including stroke) respectively with short term follow-up (Jozwiak et al., 2010; 
Yang et al., 2010). Second, because HUCB collection can only be performed at single time-
points (i.e. during birth), and the number of stem cells extracted from one donor is very 
limited, expansion of the stem cells is mandatory. Unfortunately, current methods of 
expanding HUCB cells do not preserve the quality of the hematopoietic progenitor cells 
through to the end product (Jaroscak et al., 2003; Robinson et al., 2005). Current expansion 
methods cannot make up for the cells lost in the storage process, let alone augment them to 
a suitable dosing regimen (Hows et al., 1992; Liu et al., 2006; Traycoff et al., 1995; Yao et al., 
2006). However, in the last couple of years, there have been several studies looking at ways 
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to maximize yield, storage and recovery, and expansion which require validation (Gonzalez 
et al., 2010; Koestenbauer et al., 2009; Lin et al., 2010; Song et al., 2010; Vanneaux et al., 2010; 
Zeisburger et al., 2010). Third, the cause of limited graft survival in the recipient remains to 
be determined even though the paradigm of underlying mechanisms on the functional 
improvement after stem cell transplantation has been changed from cell replacement to a 
paracrine bystander effect. The longer the grafts survive, probably the better the 
neurological or cardiac function recovers. When these hurdles are overcome in the not too 
distant future, HUCB cell therapy may become a promising treatment modality for ischemic 
diseases including stroke and MI with multiple therapeutic potentials and a longer effective 
time frame in a single transplant that no other currently available pharmacological agent 
could mimic. 
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